Biologically based myocardial regeneration: Is there a role for the surgeon?

Current Opinion in Cardiology

Volumn 21, Issue 6, 2006, Pages 589-594

  Boodhwani, Munir ^a   Sodha, Neel R ^a   Sellke, Frank W ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Cell transplantation; Coronary artery disease; Growth factors; Stem cells

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; VASCULOTROPIN; VASCULOTROPIN C;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANGIOGENESIS; BONE MARROW CELL; CANCER; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEVER; GENE THERAPY; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE PERFUSION; HEART MUSCLE REVASCULARIZATION; HUMAN; INFLAMMATION; LACTATE DEHYDROGENASE BLOOD LEVEL; MESENCHYME CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SKELETAL MUSCLE; STEM CELL; SURGEON;

BIOLOGICAL THERAPY; CARDIOLOGY; CORONARY ARTERIOSCLEROSIS; ENDOTHELIUM; FIBROBLAST GROWTH FACTORS; HUMANS; MYOCARDIAL REVASCULARIZATION; PHYSICIAN'S ROLE; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 33750347593     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000245734.17217.a4     Document Type: Review

References (45)

1. World Health Organization (WHO). The atlas of heart disease and stroke. Geneva: World Health Organization; 2004.
2. American Heart Association. Heart disease and stroke statistics: 2005 update. Dallas: American Heart Association; 2005.
3. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407:242-248.
4. Simons M. Angiogenesis: where do we stand now? Circulation 2005; 111:1556-1566. This is an excellent overview of the biology of growth factors as well as a discussion of relevant issues in angiogenic therapy.
5. Lopez JJ, Laham RJ, Carrozza JP, et al. Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response. Am J Physiol Heart Circ Physiol 1997; 273 (3 Pt 2):H1317-H1323.
6. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31.
7. Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003; 107:1359-1365.
8. Rana JS, Mannam A, Donnell-Fink L, et al. Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease. Am J Cardiol 2005; 95:1456-1459. This interesting study demonstrated the persistent placebo effect in patients with end-stage coronary artery disease.
9. Kleiman NS, Califf RM. Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000 American College of Cardiology. J Am Coll Cardiol 2000; 36:310-325.
10. Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002; 105:788-793.
11. Ruel M, Laham RJ, Parker JA, et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg 2002; 124:28-34.
12. Laham RJ, Rezaee M, Post M, et al. Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. Drug Metab Dispos 1999; 27:821-826.
13. Ruel M, Wu GF, Khan TA, et al. Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a Swine endothelial dysfunction model. Circulation 2003; 108 (Suppl 1):II335-II340.
14. Boodhwani M, Nakai Y, Mieno S, et al. Hypercholesterolemia impairs the myocardial angiogenic response in a swine model of chronic ischemia: role of endostatin and oxidative stress. Ann Thorac Surg 2006; 81:634-641. The authors provide a demonstration of the antiangiogenic influences of hypercholesterolemia on the angiogenic response in swine.
15. Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002; 105:2012-2018.
16. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002; 105:1291-1297.
17. Hedman M, Hartikainen J, Syvanne M, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003; 107:2677-2683.
18. Kastrup J, Jorgensen E, Ruck A, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 2005; 45:982-988. This recent clinical trial evaluated gene-based delivery of VEGF in patients with ischemic cardiac disease.
19. Boodhwani M, Nakai Y, Voisine P, et al. High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response. Circulation 2006; 114 (1 Suppl):I402-I408.
20. Voisine P, Li J, Bianchi C, et al. Effects of L-arginine on fibroblast growth factor 2-induced angiogenesis in a model of endothelial dysfunction. Circulation 2005; 112 (9 Suppl):I202-I207. This is a demonstration of the pro-endothelial and pro-angiogenic effects of L-arginine in hypercholesterolemic swine.
21. Laflamme MA, Murry CE. Regenerating the heart. Nat Biotechnol 2005; 23:845-856. This an excellent review of different cell types that have been used in preclinical or clinical studies for end-stage cardiac disease.
22. Reinecke H, Minami E, Poppa V, Murry CE. Evidence for fusion between cardiac and skeletal muscle cells. Circ Res 2004; 94:e56-e60.
23. Taylor DA, Atkins BZ, Hungspreugs P, et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med 1998; 4:929-933.
24. Menasche P, Hagege AA, Scorsin M, et al. Myoblast transplantation for heart failure. Lancet 2001; 357:279-280.
25. Menasche P, Hagege AA, Vilquin JT, et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J Am Coll Cardiol 2003; 41:1078-1083.
26. Balsam LB, Wagers AJ, Christensen JL, et al. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 2004; 428:668-673.
27. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410:701-705.
28. Kocher AA, Schuster MD, Szabolcs MJ, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 7:430-436.
29. Alvarez-Dolado M, Pardal R, Garcia-Verdugo JM, et al. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature 2003; 425:968-973.
30. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000; 95:952-958.
31. Gehling UM, Ergun S, Schumacher U, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000; 95:3106-3112.
32. Urbich C, Aicher A, Heeschen C, et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 2005; 39:733-742.
33. Loomans CJ, De Koning EJ, Staal FJ, et al. Endothelial progenitor cell dysfunction in type 1 diabetes: another consequence of oxidative stress? Antioxid Redox Signal 2005; 7 (11-12):1468-1475.
34. Heeschen C, Lehmann R, Honold J, et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 2004; 109:1615-1622.
35. Ruel M, Suuronen EJ, Song J, et al. Effects of off-pump versus on-pump coronary artery bypass grafting on function and viability of circulating endothelial progenitor cells. J Thorac Cardiovasc Surg 2005; 130:633-639.
36. Caplan AI, Bruder SP. Mesenchymal stem cells: building blocks for molecular medicine in the 21st century. Trends Mol Med 2001; 7:259-264.
37. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004; 95:9-20.
38. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143-147.
39. Schachinger V, Assmus B, Britten MB, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 2004; 44:1690-1699.
40. Assmus B, Schachinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002; 106:3009-3017.
41. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 2006; 113:1287-1294. This randomized clinical trial evaluated the efficacy of bone marrow cell delivery in patients with acute myocardial infarction.
42. Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004; 364:141-148.
43. Patel AN, Geffner L, Vina RF, et al. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: a prospective randomized study. J Thorac Cardiovasc Surg 2005; 130:1631-1638. This clinical trial demonstrated functional benefit of stem cell delivery with concomitant cardiac surgery.
44. Kang HJ, Kim HS, Zhang SY, et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 2004; 363:751-756.
45. Simons M, Bonow RO, Chronos NA, et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. Circulation 2000; 102:E73-E86.